Cargando…

Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety

Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background  Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavana, Sasan, Argani, Hassan, Gholamin, Sharareh, Razavi, Seyed‐Mostafa, Keshtkar‐Jahromi, Marzieh, Talebian, Amir S., Moghaddam, Keivan G., Sepehri, Zahra, Azad, Talat M., Keshtkar‐Jahromi, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942082/
https://www.ncbi.nlm.nih.gov/pubmed/21955954
http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x
_version_ 1782442379055202304
author Tavana, Sasan
Argani, Hassan
Gholamin, Sharareh
Razavi, Seyed‐Mostafa
Keshtkar‐Jahromi, Marzieh
Talebian, Amir S.
Moghaddam, Keivan G.
Sepehri, Zahra
Azad, Talat M.
Keshtkar‐Jahromi, Maryam
author_facet Tavana, Sasan
Argani, Hassan
Gholamin, Sharareh
Razavi, Seyed‐Mostafa
Keshtkar‐Jahromi, Marzieh
Talebian, Amir S.
Moghaddam, Keivan G.
Sepehri, Zahra
Azad, Talat M.
Keshtkar‐Jahromi, Maryam
author_sort Tavana, Sasan
collection PubMed
description Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background  Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives  To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods  Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results  Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0·034) than men. Twenty‐four‐hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0·477, P = 0·003] and H3N2 (CC = 0·352, P = 0·028) antigens. Serum angiotensin‐converting enzyme correlated negatively with antibody response against B antigen (CC = −0·331, P = 0·040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = −0·377, P = 0·035). No major adverse events or disease flare‐up was observed during follow‐up. Conclusions  In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study.
format Online
Article
Text
id pubmed-4942082
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-49420822016-07-18 Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety Tavana, Sasan Argani, Hassan Gholamin, Sharareh Razavi, Seyed‐Mostafa Keshtkar‐Jahromi, Marzieh Talebian, Amir S. Moghaddam, Keivan G. Sepehri, Zahra Azad, Talat M. Keshtkar‐Jahromi, Maryam Influenza Other Respir Viruses Original Articles Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background  Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives  To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods  Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results  Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0·034) than men. Twenty‐four‐hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0·477, P = 0·003] and H3N2 (CC = 0·352, P = 0·028) antigens. Serum angiotensin‐converting enzyme correlated negatively with antibody response against B antigen (CC = −0·331, P = 0·040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = −0·377, P = 0·035). No major adverse events or disease flare‐up was observed during follow‐up. Conclusions  In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study. Blackwell Publishing Ltd 2011-09-28 2012-03 /pmc/articles/PMC4942082/ /pubmed/21955954 http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x Text en © 2011 Blackwell Publishing Ltd
spellingShingle Original Articles
Tavana, Sasan
Argani, Hassan
Gholamin, Sharareh
Razavi, Seyed‐Mostafa
Keshtkar‐Jahromi, Marzieh
Talebian, Amir S.
Moghaddam, Keivan G.
Sepehri, Zahra
Azad, Talat M.
Keshtkar‐Jahromi, Maryam
Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title_full Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title_fullStr Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title_full_unstemmed Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title_short Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
title_sort influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942082/
https://www.ncbi.nlm.nih.gov/pubmed/21955954
http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x
work_keys_str_mv AT tavanasasan influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT arganihassan influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT gholaminsharareh influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT razaviseyedmostafa influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT keshtkarjahromimarzieh influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT talebianamirs influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT moghaddamkeivang influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT sepehrizahra influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT azadtalatm influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety
AT keshtkarjahromimaryam influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety